Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study-Reference-Cited by-同舟云学术

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study

Published:2018-09 Issue: Volume:101 Page:201-209
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Horn Leora,Gettinger Scott N.,Gordon Michael S.,Herbst Roy S.,Gandhi Leena,Felip Enriqueta,Sequist Lecia V.,Spigel David R.,Antonia Scott J.,Balmanoukian Ani,Cassier Philippe A.,Liu Bo,Kowanetz Marcin,O'Hear Carol,Fassò Marcella,Grossman William,Sandler Alan,Soria Jean-Charles

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion;Dong;Nat Med,2002

2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

3. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production;Brown;J Immunol,2003

4. PD-L2 is a second ligand for PD-1 and inhibits T cell activation;Latchman;Nat Immunol,2001

5. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer;Powles;Nature,2014

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16

2. Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer;Thoracic Cancer;2024-03-25

3. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

4. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2024-01

5. Meta-analysis of Censored Adverse Events;The New England Journal of Statistics in Data Science;2024